Israel - English - Ministry of Health

unipharm ltd, israel - zopiclone - tablets - zopiclone 3.75 mg - zopiclone - hypnotic.

Israel - English - Ministry of Health

unipharm ltd, israel - zopiclone - tablets - zopiclone 7.5 mg - zopiclone - hypnotic when the disorder of insomnia is severe and disabling.

Israel - English - Ministry of Health

unipharm ltd, israel - zopiclone - tablets - zopiclone 7.5 mg - zopiclone - zopiclone - hypnotic when the disorder of insomnia is severe and disabling.

Israel - English - Ministry of Health

unipharm ltd, israel - zopiclone - tablets - zopiclone 3.75 mg - zopiclone - zopiclone - hypnotic.

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - bladder sphincter 6x thyroid 6x, 12x causticum 12x equisetum hyemale 12x ferrum phosphoricum 12x kreosotum 12x pulsatilla 12x calcarea phosphorica 12x, 30x - for the temporary relief of involuntary urination during sleep.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

European Union - English - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - soliris is indicated in adults and children for the treatment of:paroxysmal nocturnal haemoglobinuria (pnh).evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of:refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive (see section 5.1).neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 0.025 mg - wafer - excipient ingredients: gelatin; mannitol; citric acid - nocdurna is indicated for the treatment of nocturia due to idiopathic nocturnal polyuria in adults who awaken two or more times each night to void and have not responded to lifestyle measures.,nocturnal polyuria should be confirmed on the basis of a 24 hour urine frequency-volume diary. it is defined as greater than 33% of urine passed overnight. secondary causes of nocturia should be excluded (see contraindications and precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - eculizumab, quantity: 300 mg - injection, intravenous infusion - excipient ingredients: polysorbate 80; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - soliris is indicated for the treatment of patients with: ? paroxysmal nocturnal haemoglobinuria (pnh) to reduce haemolysis. ? atypical haemolytic uraemic syndrome (ahus). ? adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin-4 (aqp4) antibody-positive. soliris is not intended for acute treatment of a nmosd relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 240 microgram (equivalent: desmopressin acetate, qty 272 microgram) - wafer - excipient ingredients: mannitol; citric acid; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 120 microgram (equivalent: desmopressin acetate, qty 136 microgram) - wafer - excipient ingredients: citric acid; mannitol; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.